Inventiva (NASDAQ:IVA) Trading 3.2% Higher – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price traded up 3.2% during mid-day trading on Monday . The stock traded as high as $4.64 and last traded at $4.6250. 18,199 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 90,330 shares. The stock had previously closed at $4.48.

Analysts Set New Price Targets

IVA has been the subject of several recent research reports. Canaccord Genuity Group reissued a “buy” rating and set a $20.00 price objective on shares of Inventiva in a research report on Tuesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Wednesday, October 8th. HC Wainwright lifted their price target on Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Wall Street Zen upgraded shares of Inventiva to a “hold” rating in a research note on Saturday, October 18th. Finally, Guggenheim reduced their price objective on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Inventiva has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

Inventiva Trading Up 1.5%

The business has a fifty day moving average price of $4.41 and a 200-day moving average price of $4.40.

Institutional Investors Weigh In On Inventiva

A number of large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new position in shares of Inventiva in the 3rd quarter worth $649,000. NewEdge Advisors LLC bought a new position in Inventiva in the 3rd quarter worth approximately $116,000. Creative Planning purchased a new stake in Inventiva during the 2nd quarter valued at approximately $32,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after buying an additional 9,212 shares during the last quarter. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.